glp 1 agonist fda approval Novo Nordisk's Wegovy® pill (oral semaglutide 25 mg, once daily) has just been approved by the US as the first oral GLP‑1 receptor for long‑term weight management and CV risk The New Weight Management Meds

Semaglutide is a pure GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a hormone your gut releases after eating

High costs serve as barrier to care High out-of-pocket costs for people without insurance coverage remain a key factor in determining who can benefit from GLP-1 medications and who cannot, said Tracy Svenyach, PhD, director of policy strategy and alliance at the Obesity Action Coalition

"When it comes to the internet, be skeptical

Rawshani A, Rawshani A, Franzen S, et al

We know what he is going to say

The growth is attributed to the increasing demand for noninvasive and patient-friendly treatment options